重组人白介素-11治疗肿瘤相关性血小板减少症效果影响因素

Analysis of the Factors Influencing Effect of Recombinant Human Interleukin-11 on Thrombocytopenia Patients

目的探讨重组人白介素-11(rh IL-11)治疗肿瘤相关性血小板减少症(chemotherapy-induced thrombocytopenia,CIT)效果的影响因素。方法对应用rh IL-11治疗晚期CIT 157例的临床资料进行回顾性分析,观察性别、年龄、骨转移、肝癌并肝硬化、血液系恶性肿瘤、放疗史、接受化疗周期数等因素对疗效的影响并进行多因素相关分析。结果本组157例CIT均予rh IL-11治疗14 d,其中显效46例(29.3%),良效12例(7.6%),有效24例(15.3%),无效75例(46.1%),总有效率为53.9%(82/157)。年龄、罹患肝癌及血液系恶性肿瘤与rh IL-11治疗CIT的效果有相关性(P<0.05),而性别、骨转移、放疗史、化疗>6周期则与疗效无明显相关性(P>0.05)。经两分类Logistic回归模型分析显示,年龄、肝癌并肝硬化、血液系恶性肿瘤、放疗史为rh IL-11疗效的影响因素。结论 rh IL-11的疗效与CIT患者的年龄、肝癌并肝硬化、血液系恶性肿瘤、放疗史等因素有关。

Objective To detect the factors influencing effect of Recombinant Human Interleukin-11 on thrombocytopenia patients. Methods 157 patients were enrolled in this study. Age,gender,bone metastasis,hepatoma patients with cirrhosis,non solid tumor,radiotherapy,and chemotherapy were analyzed. Results All the patients in the group were given rh IL-11 therapy,and46 cases were markedly effective（ 29. 3%）,12 cases（ 7. 6%） good,24 cases（ 15. 3%） effective and 75 cases（ 47. 8%） invalid,and total efficiency rate was 52. 2%（ 82 /157）; age,hepatoma patients,malignant tumor of blood system showed significant differences respectively（ P〈0. 05）. Gender,bone metastasis,radiotherapy,chemotherapy showed no significant difference respectively（ P〈0. 05）. Four influential factors finally entered into the model of Logistic regression： age,hepatoma patients with cirrhosis,malignant tumor of blood system and radiotherapy. Conclusion The effect of Recombinant Human Interleukin-11 on thrombocytopenia patients with malignant tumor is related with age,hepatoma patients with cirrhosis and non solid tumor.